CPVT: Difference between revisions

Jump to navigation Jump to search

CPVT (view source)

Revision as of 05:04, 22 March 2013

962 bytes added ,  22 March 2013
no edit summary
mNo edit summary
No edit summary
Line 1: Line 1:
[[File:ECG000032.jpg|thumb|300px|right|The ECG of a patient with CPVT in rest is normal]]
''Auteur: Louise R.A. Olde Nordkamp''
[[File:ECG000033.jpg|thumb|300px|right|The ECG of the same patient with CPVT during exercise. Asterisks mark polymorphic ventricular beats.]]
'''Catecholaminergic Polymorphic Ventricular Tachycardia''' is a congenital disease that leads to exercise induced [[Ventricular Arrhythmias|ventricular arrhythmias]] and / or syncope and carries an increased risk of sudden death.


'''Characteristics of CPVT:'''
''Supervisor: Arthur A.M. Wilde''
*The mean onset of arrhythmias is 7-9 years
*Absence of structural cardiac abnormalities
*Normal resting ECG
*Syncope during physical activity or emotional stress


'''Diagnosis'''
'''Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)''' refers to a hereditary disease that is associated with exercise (or adrenergic) induced ventricular arrhythmias and/or cardiac syncope and carries an increased risk of sudden cardiac death.
*The diagnosis is based on the patient's clinical history (dizziness or syncope induced by exercise or emotional stress and a family history containing syncope or sudden death in young relatives related to similar triggers) and reproducible ventricular arrhythmias during [[Exercise Testing|exercise testing]]. The complexity of these arrhythmias often increases with increasing work load, starting with [[Ventricular Premature Beats]], and ending with bidirectional [[Ventricular Tachycardia|ventricular tachycardia]] to [[Ventricular Tachycardia|polymorphic ventricular tachycardia]].  
 
*Two genes have been linked to CPVT. Both lead to a defect in intracellular calcium metabolism:
===General features===
** the hRyR2 gene, coding for the cardiac ryanodine receptor: ([[w:OMIM|OMIM™]] link {{OMIM2|180902}}) (50-55 % of patients)
*The diagnosis is based on adrenergic-induced bidirectional and polymorphic ventricular tachycardia.
** the CASQ2 gene, coding for the calsequestrine protein: ([[w:OMIM|OMIM™]] link {{OMIM2|114251}}) (1-2 % of patients)
*The resting ECG is normal and the heart is structurally normal.
*It is an inheritable cardiac arrhythmia syndrome with an autosomal dominant (RyR2) or recessive (CASQ2) inheritance.
*The arrhythmias typically occur in children and adolescents.
*The mortality rate is approximately 31% by the age of 30 years, if untreated.
*The prevalence is estimated to be 1:10.000 in Europe.
 
Clinical diagnosis
The clinical diagnosis of CPVT is confirmed in an individual with polymorphic VT reproducibly induced during exercise tests, isoproterenol infusion or emotion and exercise.
 
Patients present themselves most often with syncope or even an out-of-hospital cardiac arrest, usually during the first or second decade of life. The symptoms are always triggered by exercise or emotional stress. A family history of exercise-related syncope, seizure or sudden death is reported in 30% of the patients.
 
Family members of patients with CPVT who also carry a mutation in a CPVT-associated gene are often asymptomatic.
 
===Physical examination===
Patients can present with symptoms of arrhythmias during exercise:
*Out-of-hospital-cardiac-arrest
*Syncope, pre-syncope (weakness, lightheadedness, dizziness)
 
===ECG tests===
[[File:Ventricular_complexes.png|thumb|300px|right]]
The resting ECG in CPVT is normal. However, there is a progressive ventricular ectopy as heart rate increases during exercise or isoproterenol infusion. Both the frequency and the complexity of the ventricular ectopy increase with the work load. It generally starts with monomorphic premature ventricular complexes (PVCs) and is followed bigemini and subsequently more complex arrhythmias, including doublets triplets, bidirectional ventricular tachycardia to polymorphic ventricular tachycardia. Most of the times, the arrhythmia is self-limiting. However, in some patients, especially if exercise is continued, repeated polymorphic VTs can deteriorate in ventricular fibrillation and sudden cardiac death.
 
Genetic diagnosis
[[File:CPVT.jpg|thumb|300px|left]]
CPVT is caused by mutations in genes involved in the calcium homeostasis of cardiac cells. Four disease-causing genes have been identified: the ryanodine receptor 2 gene (RyR2) (60%), the cardiac calsequestrin 2 gene (CASQ2) (1-2%), the calmodulin gene (CALM1) (<1%) and the TRDM gene (<1%). Mutant RyR2 channels have a gain-of-function effect, resulting in excessive calcium release during sympathetic activation. Mutant CASQ2 causes loss of buffering capacity for calcium of the sarcoplasmatic reticulum. The mutations cause excessive calcium in the myocyte cytosol generating depolarizing membrane currents, which in turn lead to delayed afterdepolarizations and cardiac arrhythmias.


'''Treatment'''<cite>sumitomo</cite>
* Beta-blockers
* [[ICD|ICD (Internal Cardioverter Defibrillator)]] implantation combined with beta-blockers in CPVT patients who survived a cardiac arrest or patients with syncope and/or documented sustained [[Ventricular Tachycardia|ventricular tachycardia]] despite beta-blocker therapy.<cite>ACC2006</cite>
* Surgical left cardiac sympathetic denervation in selected patients whose symptoms and/or ventricular arrhythmias are not controlled by pharmacologic therapy <cite>Wilde</cite><cite>Collura</cite>
* Avoid competitive and other strenuous exercise


===References===
===References===
Line 30: Line 43:
#Priori pmid=12093772
#Priori pmid=12093772
#ryanodine pmid=22787013
#ryanodine pmid=22787013
</biblio>
</biblio>''
Retrieved from "https://www.textbookofcardiology.org/wiki/Special:MobileDiff/2221"

Navigation menu